Glucosamine and chondroitin may not positively affect joint health according to a recent study released in the Journal of Arthritis & Rheumatism. However, as main stream media outlets across the country have picked up on this story, it is worth noting that researchers are uncertain about their findings. “The validity and mechanisms of this novel observation are uncertain but could be related to altered absorption of glucosamine,” one researcher commented.
The researchers also admit they cannot draw any definitive conclusions from the observation and suggest changes for future trials. Daniel Fabricant, Ph.D., vice president of scientific and regulatory affairs for the Natural Products Association, commented on the findings, “Bottom line: this is one study -- it doesn't represent the totality of the research on glucosamine/chondroitin, which is very positive overall. Especially when compared to the few other options for osteoarthritis, it’s one of the few options without dangerous side effects.”
Sales of glucosamine and chondroitin grew 3.5% in 2007, churning out $831 million in the U.S. The domestic market has risen significantly since 1997, producing an 18% CAGR and adding more than $650 million in sales. NBJ will monitor the segment in the months to come to see if sales are negatively impacted by the University of Utah study.